GlassScriptPhysician profile
Sarah Yu
NPI 1629565460
$2,163.09
in general payments reported to CMS, 2019-2025
24 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.13 · 2022: $84.76 · 2023: $91.62 · 2024: $645 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325.32 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $252.51 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $215.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $201.83 | 2022-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.46 | 2021-2025 | Jardiance, Ofev |
| Pfizer INC. | $123.57 | 2022-2025 | |
| Corcept Therapeutics | $104.91 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $82.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $70.99 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $66.59 | 2025 | |
| Inspire Medical Systems, INC. | $58.04 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $55.57 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $54.54 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $51.57 | 2024-2025 | Voquezna |
| Abbvie INC. | $44.66 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.33 | 2024-2025 | Dexcom G6 Transmitter |
| Verity Pharmaceuticals INC. | $44.25 | 2025 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $41.78 | 2024 | |
| Abbott Laboratories | $28.05 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.12 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $24.26 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $17.60 | 2023 | |
| Eisai INC. | $17.20 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.96 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.